View More Recent Stories

Sep 12, 2024 08:31AM Emergent BioSolutions (EBS) Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga Treatment for Ebola
Sep 3, 2024 07:09AM Emergent BioSolutions (EBS) Successfully Refinances Debt, Strengthens Financial Profile
Sep 3, 2024 06:11AM Increasing unusual call option volume: LUNR K EBS FLR DG ESTC DINO ICLN
Aug 30, 2024 08:16AM Emergent BioSolutions (EBS) Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness
Aug 30, 2024 06:55AM Emergent BioSolutions (EBS) ACAM2000 Receives U.S. FDA Approval for Mpox Indication
Aug 20, 2024 11:36AM Emergent BioSolutions (EBS) Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals
Aug 19, 2024 05:13PM Emergent BioSolutions (EBS) Responds to Mpox Public Health Emergency as Cases Surge in Africa
Aug 19, 2024 08:59AM Mpox-linked stocks extend rally into second week
Aug 7, 2024 04:32AM Emergent BioSolutions (EBS) Misses Q2 EPS by 137c; offers guidance
Aug 6, 2024 08:01AM Emergent BioSolutions (EBS) Expands NARCAN Nasal Spray Distribution Capabilities to Enhance Customer Delivery Experience Across the Country
Jul 22, 2024 08:06AM Emergent BioSolutions (EBS) Announces Shelf-Life Extension for NARCAN Nasal Spray in Canada
Jul 8, 2024 05:01PM Emergent BioSolutions (EBS), Johnson & Johnson (JNJ) Settle Claims Over Vaccine Manufacturing Pact - Bloomberg
Jul 2, 2024 08:14AM Emergent BioSolutions (EBS) Wins $250M+ in US Govt Contract Modifications
Jun 20, 2024 07:07AM Emergent BioSolutions (EBS) PT Raised to $8 at Benchmark
Jun 20, 2024 07:01AM Emergent BioSolutions (EBS) Sells Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30M
View More Recent Stories